Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
492
mi
from 43215
Birmingham, AL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01038 Boehringer Ingelheim Investigational Site
1949
mi
from 43215
Encinitas, CA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01038 Boehringer Ingelheim Investigational Site
1949
mi
from 43215
Encinitas, CA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1245.25.10103 Boehringer Ingelheim Investigational Site
1984
mi
from 43215
Encino, CA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1245.25.10103 Boehringer Ingelheim Investigational Site
1984
mi
from 43215
Encino, CA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
1972
mi
from 43215
Los Angeles, CA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01130 Boehringer Ingelheim Investigational Site
436
mi
from 43215
Atlanta, GA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01130 Boehringer Ingelheim Investigational Site
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01330 Boehringer Ingelheim Investigational Site
299
mi
from 43215
Arlington Heights, IL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01330 Boehringer Ingelheim Investigational Site
299
mi
from 43215
Arlington Heights, IL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.14.1261 Boehringer Ingelheim Investigational Site
284
mi
from 43215
Skokie, IL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.14.1261 Boehringer Ingelheim Investigational Site
284
mi
from 43215
Skokie, IL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1311.4.10100 Boehringer Ingelheim Investigational Site
311
mi
from 43215
West Dundee, IL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1311.4.10100 Boehringer Ingelheim Investigational Site
311
mi
from 43215
West Dundee, IL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1311.4.10044 Boehringer Ingelheim Investigational Site
179
mi
from 43215
Plainfield, IN
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1311.4.10044 Boehringer Ingelheim Investigational Site
179
mi
from 43215
Plainfield, IN
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1222.29.11002 Boehringer Ingelheim Investigational Site
624
mi
from 43215
Overland Park, KA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1222.29.11002 Boehringer Ingelheim Investigational Site
624
mi
from 43215
Overland Park, KA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.14.1172 Boehringer Ingelheim Investigational Site
188
mi
from 43215
Louisville, KY
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.14.1172 Boehringer Ingelheim Investigational Site
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01270 Boehringer Ingelheim Investigational Site
164
mi
from 43215
Ann Arbor, MI
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01270 Boehringer Ingelheim Investigational Site
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01104 Boehringer Ingelheim Investigational Site
629
mi
from 43215
Fridley, MN
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01104 Boehringer Ingelheim Investigational Site
629
mi
from 43215
Fridley, MN
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1311.2.10001 Boehringer Ingelheim Investigational Site
448
mi
from 43215
East Windsor, NJ
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1311.2.10001 Boehringer Ingelheim Investigational Site
448
mi
from 43215
East Windsor, NJ
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
348
mi
from 43215
Charlotte, NC
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
98
mi
from 43215
Cincinnati, OH
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
2026
mi
from 43215
Portland, OR
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01214 Boehringer Ingelheim Investigational Site
614
mi
from 43215
Johnston, RI
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01214 Boehringer Ingelheim Investigational Site
614
mi
from 43215
Johnston, RI
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
991
mi
from 43215
Houston, TX
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
1138
mi
from 43215
San Antonio, TX
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1301.1.5799 Boehringer Ingelheim Investigational Site
993
mi
from 43215
Webster, TX
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1301.1.5799 Boehringer Ingelheim Investigational Site
993
mi
from 43215
Webster, TX
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1245.25.10004 Boehringer Ingelheim Investigational Site
423
mi
from 43215
Norfolk, VA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1245.25.10004 Boehringer Ingelheim Investigational Site
423
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.14.1259 Boehringer Ingelheim Investigational Site
1778
mi
from 43215
Spokane, WA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.14.1259 Boehringer Ingelheim Investigational Site
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.128.10017 Boehringer Ingelheim Investigational Site
394
mi
from 43215
Saint Louis, MO
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.128.10017 Boehringer Ingelheim Investigational Site
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Wallace Medical Group
1979
mi
from 43215
Beverly Hills, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Wallace Medical Group
1979
mi
from 43215
Beverly Hills, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Encino Research Center
1984
mi
from 43215
Encino, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Encino Research Center
1984
mi
from 43215
Encino, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
1942
mi
from 43215
La Mesa, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
1942
mi
from 43215
La Mesa, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
1945
mi
from 43215
Oceanside, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
1945
mi
from 43215
Oceanside, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
1951
mi
from 43215
San Diego, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Shahram Jacobs MD, INC
1980
mi
from 43215
Sherman Oaks, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Shahram Jacobs MD, INC
1980
mi
from 43215
Sherman Oaks, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Horizons Clinical Research Center, LLC
1159
mi
from 43215
Denver, CO
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Horizons Clinical Research Center, LLC
1159
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Bioclinical Research Alliance Inc.
995
mi
from 43215
Miami, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Bioclinical Research Alliance Inc.
995
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Sanitas Reasearch, LLC
993
mi
from 43215
Miami, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Sanitas Reasearch, LLC
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
746
mi
from 43215
Ocala, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
746
mi
from 43215
Ocala, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
795
mi
from 43215
Orlando, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research Group, LLC
158
mi
from 43215
Indianapolis, IN
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research Group, LLC
158
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
624
mi
from 43215
Overland Park, KA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
624
mi
from 43215
Overland Park, KA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Bay State Clinical Trials, Inc.
636
mi
from 43215
Watertown, MA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Bay State Clinical Trials, Inc.
636
mi
from 43215
Watertown, MA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
1758
mi
from 43215
Las Vegas, NV
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
1758
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
84
mi
from 43215
Cincinnati, OH
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
84
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc
1
mi
from 43215
Columbus, OH
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Clinical Research
377
mi
from 43215
Anderson, SC
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Clinical Research
377
mi
from 43215
Anderson, SC
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Palmetto Clinical Trial Services Llc
367
mi
from 43215
Fountain Inn, SC
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Palmetto Clinical Trial Services Llc
367
mi
from 43215
Fountain Inn, SC
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research
350
mi
from 43215
Greer, SC
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research
350
mi
from 43215
Greer, SC
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Austin Institute for Clinical Research, Inc.
1052
mi
from 43215
Pflugerville, TX
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Austin Institute for Clinical Research, Inc.
1052
mi
from 43215
Pflugerville, TX
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
1137
mi
from 43215
San Antonio, TX
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
1137
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
National Clinical Research - Richmond, Inc.
335
mi
from 43215
Richmond, VA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
National Clinical Research - Richmond, Inc.
335
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Medical Centre Asklepii, OOD
5118
mi
from 43215
Dupnitsa,
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Medical Centre Asklepii, OOD
5118
mi
from 43215
Dupnitsa,
Click here to add this to my saved trials
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)
A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Glenmark Investigational Site 1
442
mi
from 43215
New York, NY
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)
A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Glenmark Investigational Site 1
442
mi
from 43215
New York, NY
Click here to add this to my saved trials